REG - MaxCyte, Inc. MaxCyte, Inc. - MXCR - MaxCyte Appoints Ali Soleymannezhad as CCO

MaxCyteAnnouncement

10/10/2024 13:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241010:nRSJ7240Ha&default-theme=true

RNS Number : 7240H  MaxCyte, Inc.  10 October 2024

 

MaxCyte Appoints Ali Soleymannezhad as Chief Commercial Officer

 

 

Rockville, MD, Oct. 10, 2024 - MaxCyte, Inc.
(https://protect.checkpoint.com/v2/___https:/maxcyte.com/___.YzJ1OmdpbG1hcnRpbmdyb3VwOmM6bzo5NGRhMmRhOGUwZjZhMzIxM2QzMTEzMDQ2YjA0ZjQzYjo2Ojk2MGQ6M2Q0Y2M0Y2IyMzI3OGExYjcwZmZiN2YxMzNhMDYzYmY2YzNiMDBiMzZlMDQwNGVmM2JmOTc2M2U1NDMxYTc2YzpwOkY6Rg)
, (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company
providing enabling platform technologies to advance the discovery, development
and commercialization of next-generation cell-based therapeutics and
innovative bioprocessing applications, today announced the appointment of Ali
Soleymannezhad as Chief Commercial Officer, effective as of September 11,
2024.

 

In his new role, Mr. Soleymannezhad will lead MaxCyte's commercial operations
to increase adoption of the ExPERT Platform, provide best-in-class scientific,
technical and regulatory support to customers, and expand the Company's market
impact in Cell and Gene Therapy.  Prior to his role as Chief Commercial
Officer, Mr. Soleymannezhad was the Executive Vice President of Bioprocessing,
where he led global product development and marketing strategy for MaxCyte's
bioprocessing business.

 

"I am delighted to promote Ali to the role of Chief Commercial Officer," said
Maher Masoud, President and CEO of MaxCyte. "His diverse experience, skills,
and leadership at MaxCyte as Executive Vice President of Bioprocessing have
strengthened our organization's product development and commercial strategies.
We look forward to working alongside Ali as he leads our commercial efforts to
drive future growth at MaxCyte."

 

Mr. Soleymannezhad brings 20 years of technical sales, marketing, and product
development experience to his new role. Prior to Executive Vice President of
Bioprocessing at MaxCyte, he served as Executive Vice President for the
Separations and Purification business at Tosoh Bioscience and oversaw a team
of 140 employees across four global manufacturing, development, and commercial
sites. Mr. Soleymannezhad was also Vice President of Global Marketing and
Business Development and Director of Sales and Marketing-Americas at Tosoh and
served on the board of Semba Biosciences.

 

"I am excited to apply my experience in sales and marketing and global
business strategy to MaxCyte's commercial efforts," said Ali Soleymannezhad,
CCO of MaxCyte. "I look forward to working with our executive team to continue
MaxCyte's commitment to supporting our customer's Cell and Gene therapy work
in research, through the clinic, and beyond."

 

About MaxCyte

 

At MaxCyte, we pursue cell engineering excellence to maximize the potential of
cells to improve patients' lives. We have spent more than 20 years honing our
expertise by building best-in-class platforms, perfecting the art of the
transfection workflow, and venturing beyond today's processes to innovate
tomorrow's solutions. Our ExPERT™ platform, which is based on our Flow
Electroporation® technology, has been designed to support the rapidly
expanding cell therapy market and can be utilized across the continuum of the
high-growth cell therapy sector, from discovery and development through
commercialization of next-generation, cell-based medicines. The ExPERT family
of products includes: four instruments, the ATx™, STx™, GTx™ and VLx
™; a portfolio of proprietary related processing assemblies or disposables;
and software protocols, all supported by a robust worldwide intellectual
property portfolio. By providing our partners with the right technology
platform, as well as scientific, technical and regulatory support, we aim to
guide them on their journey to transform human health. Learn more at
maxcyte.com
(https://protect.checkpoint.com/v2/___https:/maxcyte.com/___.YzJ1OmdpbG1hcnRpbmdyb3VwOmM6bzozM2I1YTVmN2I2YTExNzdhYjJiYWQzMzY2ZWJlM2NkNzo2OmE1MjQ6ZjkwYTM4NTFkYzFjZTE4MDc3MzEzMDUxMzdhY2YwMjI4NmExYzRmM2IyYTQ4MGRkNjJhMTZiYmUyNzZkMWE4NDpwOlQ6Rg)
and follow us on X
(https://protect.checkpoint.com/v2/___https:/twitter.com/MaxCyte_info___.YzJ1OmdpbG1hcnRpbmdyb3VwOmM6bzozM2I1YTVmN2I2YTExNzdhYjJiYWQzMzY2ZWJlM2NkNzo2OmNlODY6NGQ3NmQ0ODY5ZWMwZGM2ZWY3YWE0YzdmMzljY2UyODM4ZTExMGI5OWRjODhlYjk5NmI3ZjcyZTNlNTIxZGE4ZDpwOlQ6Rg)
and LinkedIn
(https://protect.checkpoint.com/v2/___https:/www.linkedin.com/company/maxcyte-inc-/___.YzJ1OmdpbG1hcnRpbmdyb3VwOmM6bzozM2I1YTVmN2I2YTExNzdhYjJiYWQzMzY2ZWJlM2NkNzo2OmE5Yjg6ODI4ODYyMDRkZDU5YTY0MjUyMzY1NGQwMjczZDA2NTM5YTI1MDcxM2Y4NjgyNWUxODM5YTcxMTc4ZDJkYmRiMDpwOlQ6Rg)
.

 

Forward-Looking Statements

 

This press release contains "forward-looking statements" within the meaning of
the "safe harbor" provisions of the Private Securities Litigation Reform Act
of 1995. These statements about us and our industry involve substantial known
and unknown risks, uncertainties, and assumptions that may cause our actual
results, performance or achievements to be materially different from any
future results, performance or achievements expressed or implied by the
forward-looking statements. All statements other than statements of historical
facts contained in this press release, including statements regarding our
future results of operations or financial condition, business strategy and
plans and objectives of management for future operations, are forward-looking
statements. Forward-looking statements include, but are not limited to,
statements about the Company's projected full-year total revenue, core
revenue, and SPL program revenue and statements about possible or future
results of operations or financial position. In some cases, you can identify
forward-looking statements because they contain words such as "may," "might,"
"will," "could," "would," "should," "expect," "plan," "anticipate," "intend,"
"believe," "expect," "estimate," "seek," "predict," "future," "project,"
"potential," "continue," "contemplate," "target," the negative of these words
and similar words or expressions. These statements are inherently uncertain,
and investors are cautioned not to unduly rely on these statements. The
forward-looking statements contained in this press release, include, without
limitation, statements concerning the following: our expected future growth
and success of our business model; the size and growth potential of the
markets for our products, and our ability to serve those markets, increase our
market share, and achieve and maintain industry leadership; and our ability to
expand our customer base and enter into additional SPL partnerships.

 

These and other risks and uncertainties are described in greater detail in
Item 1A , entitled "Risk Factors," in our Annual Report on Form 10-K for the
year ended December 31, 2023, filed with the Securities and Exchange
Commission on or about March 12, 2024, as well as in discussions of potential
risks, uncertainties, and other important factors in the other filings that we
make with the Securities and Exchange Commission from time to time. These
documents are available through the Investor Menu, Financials section, under
"SEC Filings" on the Investors page of our website at
http://investors.maxcyte.com. Any forward-looking statements in this press
release are based on our current beliefs and opinions on the relevant subject
based on information available to us as of the date of such press release, and
you should not rely on forward-looking statements as predictions of future
events. We undertake no obligation to update any forward-looking statements
made in this press release to reflect events or circumstances after the date
of this press release or to reflect new information or the occurrence of
unanticipated events, except as required by law.

 

MaxCyte Contacts:

 

US IR Adviser

Gilmartin Group

David Deuchler, CFA

+1 415-937-5400

ir@maxcyte.com (mailto:ir@maxcyte.com)

 

US Media Relations

Spectrum Science

Jordan Vines

jvines@spectrumscience.com (mailto:jvines@spectrumscience.com)

+1 540-629-3137

 

Nominated Adviser and Joint Corporate Broker

Panmure Liberum

Emma Earl / Freddy Crossley

Corporate Broking

Rupert Dearden

+44 (0)20 7886 2500

 

UK IR Adviser

ICR Consilium

Mary-Jane Elliott

Chris Welsh

+44 (0)203 709 5700

maxcyte@consilium-comms.com (mailto:maxcyte@consilium-comms.com)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAKBLBFZBLEFBE